<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To search for possible antitumor promoters, we carried out a primary screening of thirty-seven dihydroagarofuran <z:chebi fb="0" ids="35189">sesquiterpenes</z:chebi> from Tripterygium wilfordii Hook fil. var. regelii Makino and Euonymus sieboldianus Blume, using their possible inhibitory effects on the Epstein-Barr virus early antigen (EBV-EA) activation which is induced by 12-O-tetradecanoylphorbol-13-<z:chebi fb="49" ids="30089,47622">acetate</z:chebi> (<z:chebi fb="6" ids="15702,53394">TPA</z:chebi>) in Raji cells </plain></SENT>
<SENT sid="1" pm="."><plain>Some of these <z:chebi fb="0" ids="35189">sesquiterpenes</z:chebi>, triptofordin F-2 (Takaishi et al., 1988), 1,2,6,8,15-pentaacetoxy-9-benzoyloxy-4-hydroxy-beta-dihydroagarofuran and triptogelin A-1 (Takaishi et al., 1990) were observed to significantly inhibit the EBV-EA activation at low doses </plain></SENT>
<SENT sid="2" pm="."><plain>Based on the results, the structural requirements for the activity of these compounds were discussed [corrected] </plain></SENT>
</text></document>